Results 281 to 289 of about 104,823 (289)

Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes

Graefe's Archive for Clinical and Experimental Ophthalmology, 2013
Elad Moisseiev, Michael Waisbourd, Adiel Barak   +2 more
exaly  

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial

Annals of Oncology, 2015
Thomas Gruenberger, John Bridgewater, Ian Chau   +2 more
exaly  

Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Annals of Oncology, 2014
A Scherpereel, V Gorbunova, R Gervais
exaly  

Bevacizumab

Reactions Weekly, 2022
openaire   +1 more source

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Annals of Oncology, 2018
P Lorigan, M Gore, Maria Marples
exaly  

FDA Drug Approval Summary: Bevacizumab (Avastin®) Plus Carboplatin and Paclitaxel as First‐Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non‐Small Cell Lung Cancer

Oncologist, 2007
Martin H Cohen, Keegan Patricia, Pazdur Richard   +2 more
exaly  

Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers

Journal of Thoracic Oncology, 2013
Jamie E Chaft, Valerie W Rusch, David J Finley   +2 more
exaly  

Bevacizumab

Reactions Weekly, 2015
openaire   +1 more source

Bevacizumab

Reactions Weekly, 2014
openaire   +2 more sources